Navigation Links
WuXi PharmaTech Announces Second-Quarter 2012 Results
Date:8/13/2012

SHANGHAI, Aug. 13, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2012.

Highlights

  • Net Revenues Increased 28.9% Year Over Year to $130.4 Million
  • Laboratory Services Net Revenues Grew 24.7% Year Over Year to $93.6 Million
  • China-Based Laboratory Services Net Revenues Increased 27.2% Year Over Year to $70.3 Million
  • U.S.-Based Laboratory Services Net Revenues Increased 17.7% Year Over Year to $23.3 Million
  • Manufacturing Services Net Revenues Grew 41.2% Year Over Year to $36.8 Million
  • Net Revenues from China Operations Exceeded $100 Million for the First Time on a Quarterly Basis
  • Share Repurchases Totaled $10.2 Million
  • GAAP Diluted Earnings Per ADS Grew 13.4% Year Over Year to $0.28
  • Non-GAAP Diluted Earnings Per ADS Increased 12.3% Year Over Year to $0.33
  • Company Increases Full-Year 2012 Revenue Guidance to $488-$498 Million
  • Management Comment"WuXi's strong operational performance continued in the second quarter," said Dr. Ge Li, Chairman and Chief Executive Officer. "Year-over-year revenue growth accelerated to 28.9%, driven by solid demand for our broad, integrated platform of services. This revenue growth was broad-based, with each of our businesses achieving double-digit growth. I'm especially proud that this was the first quarter in which our China-based operations generated more than $100 million in net revenues. I'm also pleased that WuXi's GAAP diluted earnings per ADS increased 13.4% year over year. With these results, we met or exceeded all of our guidance for revenues and margins for the second quart
    '/>"/>

    SOURCE WuXi PharmaTech (Cayman) Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
    2. WuXi PharmaTech Announces First-Quarter 2012 Results
    3. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
    4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
    5. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
    6. Comprehensive Care Corporation Announces Profitable Six Month Financial Results
    7. Tactical Medical Packs Announces New Disaster Medical Packs Equipping First Responders for Mass Casualty Incidents
    8. Echo Therapeutics Announces Second Quarter 2012 Financial Results
    9. Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
    10. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    11. 3SBio Inc. Announces Changes to Its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
    (Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
    (Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
    Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
    ... , HAMBURG , Feb. 3 ... Wound Therapy (NPWT) will assemble this week to develop a ... NPWT Expert Panel is drafting recommendations for a range of ... published clinical evidence.  Where published evidence is insufficient, the Panel ...
    ... Feb. 2 Celsis In Vitro, Inc. (Celsis IVT) ... XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. ... Illinois in Chicago .  XenoTech and Sekisui Medical ... processes and methods performed by XenoTech associated with its in ...
    Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
    (Date:9/2/2014)... 2014 4 pm EDT): In a Viewpoint published today ... , a team of Boston researchers call for the ... in the United States. The researchers from the Friedman ... Harvard University and Boston Children,s Hospital write that policies ... could both help people make meaningful dietary changes and ...
    (Date:9/2/2014)... Friendship Village of Schaumburg is proud to ... contemporary marketing presence and visually solidifies the relationship ... Senior Options,” said Stephen A. Yenchek, president and ... logo, we are making sure that our identity ... families.” , Friendship Village is a retirement community ...
    (Date:9/2/2014)... Los Angeles, CA (PRWEB) September 02, 2014 ... an article on its website titled “Why You Should ... more than 80 percent of the global population breathes ... droplets and particles of pollution lodge in the skin’s ... the body’s natural barrier to free radicals that may ...
    (Date:9/2/2014)... 2014 In a large population-based study of ... mild cognitive impairment (MCI) occurred twice more often ... Interestingly, this strong association was only observed in ... (66-80 years) the association vanished. This study is ... . , The concept of MCI describes an ...
    (Date:9/2/2014)... 02, 2014 The Dream2Walk Foundation along with ... Sept. 14th, 2014 during Spinal Cord Injury Awareness Month featuring ... England, and Chuck Ligon. Linear Automotive will be there hosting ... , Doors open at 2pm. The car show is Pre ... free pass to the concert. There will be trophies for ...
    Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
    ... Releases First-year Results of Guiding Stars, ... Rating System, SCARBOROUGH, Maine, Sept. 6 Consumer,selection ... are outpacing,selection of those that don,t in many aisles ... times faster -- according to data in the year,since ...
    ... a proven treatment -, BELLEVILLE, ON, Sept. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... in order to be able to respond to ... equine influenza outbreak.,The outbreak began in August, and ...
    ... MYL ) today announced that Mylan Pharmaceuticals Inc. has ... for its,Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, ... Carvedilol Tablets are the generic version of GlaxoSmithKline,s,Coreg(R) Tablets. ... the 12 months ending June 30, 2007, for the ...
    ... Mich. More than 10 percent of women with ... of joint and muscle pain, according to a new ... Cancer Center. , The women in the study were ... block the production of estrogen, which fuels some breast ...
    ... a national,ground beef producer, is voluntarily recalling from ... ground beef patties, sold fresh,under the Shaw,s label, ... on Wednesday September 5, 2007 approximately between 7am ... product has been removed from saledue,to concerns about ...
    ... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") said ... dividend of $0.475 per share, payable in cash,on September ... 2007. The,dividend is the third quarterly installment of the ... is a leading healthcare real estate investment trust. Its,diverse ...
    Cached Medicine News:Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 2Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4
    ... Designed for the Anterior Segment The ... lens practitioners and ophthalmologists specializing in the anterior ... emergency rooms. Video- c-mount camera on the BD ... port. Standard magnification in 10 and 16 X ...
    ... FVL is a new functional test which ... Activated Protein C Resistance caused by the ... to other commercially available methods, Pefakit APC-R ... or S, Lupus Anticoagulants, Elevated FVIII levels, ...
    ... Used for venous pressure monitoring, blood ... fluids. Turbo-Flo polyurethane PICC line sets ... Rates, Micropuncture Introducer Needle, ... be trimmed to patient specific anatomy. ...
    Assess serum Gc-globulin levels in patients with multiple trauma, fulminant liver failure, acetaminophen overdose, and sepsis....
    Medicine Products: